Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation

Authors: Cheng, Wendy Y., Avery, Robin K., Thompson-Leduc, Philippe, Cheung, Hoi Ching, Bo, Tien, Duh, Mei Sheng, Hirji, Ishan

Source: Journal of medical economics. 25(1):367-380

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185000027.0x000001&indx=1&recIds=ETOCvdc_100185000027.0x000001

Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection

Authors: Chou, Sunwen, Wu, Jingyang, Song, Kening, Bo, Tien

Source: In Antiviral Research December 2019 172

AURORA: A New Dawn.

Authors: Papanicolaou, Genovefa A, Avery, Robin K, Cordonnier, Catherine, Duarte, Rafael F, Haider, Shariq, Maertens, Johan, Peggs, Karl S, Solano, Carlos, Young, Jo-Anne H, Fournier, Martha, Murray, Rose Ann, Wu, Jingyang, Bo, Tien, Winston, Drew J

Source: Clinical Infectious Diseases; 12/15/2024, Vol. 79 Issue 6, p1535-1537, 3p

Subject Terms: HEMATOPOIETIC stem cell transplantation, PROTEIN kinase inhibitors, PATIENT safety, CYTOMEGALOVIRUS diseases, TERMINATION of treatment, CELLULAR immunity, SURGICAL complications, ANTIVIRAL agents, REINFECTION, VALGANCICLOVIR, DRUG efficacy, VIREMIA, GRANULOCYTE-colony stimulating factor, DRUG resistance, NEUTROPENIA

Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.

Authors: Schultz, Bob G., Kotton, Camille N., Jutlla, Ginita, Ressa, Riccardo, de Lacey, Tam, Chowdhury, Emtiyaz, Bo, Tien, Fenu, Elisabetta, Gelone, Daniele K., Poirrier, Jean‐Etienne, Amorosi, Stacey L.

Source: Journal of Medical Virology; Apr2024, Vol. 96 Issue 4, p1-11, 11p

Subject Terms: CYTOMEGALOVIRUS diseases, COST effectiveness, QUALITY-adjusted life years, GENOTYPES, REFRACTORY materials

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III

Authors: Ghosh, Arunabha, Shapiro, Elsa, Rust, Stewart, Delaney, Kathleen, Parker, Samantha, Shaywitz, Adam, Morte, Adelaida, Bubb, Gillian, Cleary, Maureen, Bo, Tien, Lavery, Christine, Bigger, Brian, Jones, Simon

Source: Orphanet journal of rare diseases. 12(1):1-15

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100135432317.0x000001&indx=1&recIds=ETOCvdc_100135432317.0x000001

Multinational Study Assessing Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Hematopoietic Stem Cell Transplant Recipients with Cytomegalovirus Infection and Intolerance to Anti-Cytomegalovirus Therapies

Authors: Papanicolaou, Genovefa A, Avery, Robin K., Fox, María Laura, Peggs, Karl S, Veloso, Luís, Bo, Tien, Hirji, Ishan, Davis, Kimberly

Source: In Transplantation and Cellular Therapy February 2024 30(2) Supplement:S428-S428

Economic Impact of Post-Transplant Cytomegalovirus (CMV), Including Hematopoietic Stem Cell Transplant (HSCT) and Solid Organ Transplant (SOT) Recipients Experiencing Myelosuppression or Nephrotoxicity

Authors: Hirji, Ishan, Cheng, Wendy Y., Thompson-Leduc, Philippe, Cheung, Hoi Ching, Avery, Robin, Bo, Tien, Duh, Mei Sheng

Source: Biology of blood and marrow transplantation. 26(S):S325-S326

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100100241530.0x000001&indx=1&recIds=ETOCvdc_100100241530.0x000001

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.

Authors: Chou, Sunwen, Song, Kening, Wu, Jingyang, Bo, Tien, Crumpacker, Clyde

Source: Journal of Infectious Diseases; 8/15/2022, Vol. 226 Issue 4, p576-584, 9p

Subject Terms: CYTOMEGALOVIRUSES, GANCICLOVIR, GENETIC mutation, CYTOMEGALOVIRUS diseases, ANTIVIRAL agents, TRANSFERASES, RESEARCH funding, DRUG resistance in microorganisms, PHENOTYPES, PHARMACODYNAMICS

Capacitance probe for surface dielectric constant measurements

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation

Authors: Bassel, Marielle, Romanus, Dorothy, Bo, Tien, Sundberg, Aimee K, Okala, Sandra, Hirji, Ishan

Source: Antiviral Therapy; October 2023, Vol. 28 Issue: 5

This result is not displayed to guests.
Login for full access.